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Angiopoietin-1 induces sprouting angiogenesis in vitro
Thomas I. Koblizek*, Cornelia Weiss*, George D. Yancopoulos†, Urban
Deutsch* and Werner Risau*
Sprouting of new capillaries from pre-existing blood
vessels is a hallmark of angiogenesis during embryonic
development and solid tumor growth [1]. In addition to
the vascular endothelial growth factor (VEGF) and its
receptors, the Tie receptors and their newly identified
ligands, the angiopoietins, have been implicated in the
control of blood vessel formation [2,3]. Although
‘knockouts’ of the gene encoding the Tie2 receptor, or
its activating ligand angiopoietin-1 (Ang1), result in
embryonic lethality in mice due to an absence of
remodeling and sprouting of blood vessels [4,5],
biological activity in vitro has not yet been described
for this receptor–ligand system. In an assay in which a
monolayer of endothelial cells were cultured on
microcarrier beads and embedded in three-dimensional
fibrin gels, recombinant Ang1 (0.5–10 nM) induced the
formation of capillary sprouts in a dose-dependent
manner that was completely inhibited by soluble Tie2
receptor extracellular domains. In contrast with VEGF,
which also induced sprouting of capillaries, Ang1 was
only very weakly mitogenic for endothelial cells.
Suboptimal concentrations of VEGF and Ang1 acted
synergistically to induce sprout formation. Thus, the
biological activity of Ang1 in vitro is consistent with the
specific phenotype of mice deficient in Tie2 or Ang1.
The data suggest that, like in other developmental
systems, blood vessel formation requires a hierarchy of
master-control genes in which VEGF and angiopoietins,
along with their receptors, are amongst the most
important regulators. 
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Results and discussion
Previous attempts to detect biological activity of the newly
identified angiopoietin ligands for the Tie2 receptors in
vitro have failed [5–7]. Because one of the most important
phenotypes in Tie2-deficient mice is the absence of capil-
lary sprouts in the neural tube [4], we have taken advan-
tage of an in vitro sprouting assay [8] to investigate the
biological activities of the angiopoietins. Adrenal-cortex-
derived microvascular endothelial (ACE) cells were culti-
vated on microcarrier (MC) beads until they had formed a
confluent monolayer. These beads were then embedded
into fibrin gels containing the various factors or controls.
Initially, cell culture supernatants of a chinese hamster
ovary (CHO) cell line stably transfected with an expression
plasmid for Ang1, and, subsequently, purified recombinant
Ang1* [7], were used to study the activity of Ang1 in vitro.
Biological activity of recombinant Ang1 and Ang1* was
confirmed by their high-affinity binding to, and stimula-
tion of the tyrosine kinase activity of, the Tie2 receptor in
vitro [5–7]. Ang1* is a variant of Ang1 that is used primarily
because it is much easier to produce than Ang1, which
cannot be made easily in quantities sufficient for experi-
mental uses (S. Davis, T.H. Aldrich, N. Papadopoulos,
T.J. Daly, J. Goldberg, V. Jain and G.D.Y., unpublished
observations); in addition, Ang1* is also not susceptible to
inhibition with Ang2. Ang1* consists of the first 73
residues of human Ang2 —beginning with the initiator
methionine and ending with the sequence DAPLEY (in
the single-letter amino-acid code) — fused to the portion
of human Ang1 beginning at residue 77 with the sequence
DFSSQ and extending to the carboxyl terminus. In addi-
tion, the cysteine corresponding to position 265 of human
Ang1 is replaced by a serine. 
Ang1-containing supernatants, and also purified Ang1*,
induced the formation of capillary sprouts, whereas super-
natants of control cells did not (Figure 1). Endothelial
cells migrated from the confluent monolayer and
extended long filopodia. Long sprouts consisted of several
cells forming a lumen as described before [9]. This
process closely resembles sprout formation in vivo. Deple-
tion of Ang1 from the CHO-conditioned medium by pre-
adsorption to a Tie2–immunoglobulin G (IgG) column
(data not shown), or incorporation of the Tie2–IgG into
the fibrin gel, completely inhibited sprout formation.
Endothelial cells lacking the Tie2 receptor (derived from
Tie2-receptor-deficient mice) did not respond to Ang1 by
sprouting, in contrast to wild-type endothelial cells (data
not shown). Taken together, these results clearly demon-
strated the specificity of Ang1 action. Quantification of
sprout formation revealed a more than 10-fold increase in
the number of sprouts with a length exceeding the diame-
ter of the bead, which was used as an internal standard
(Figure 2). Figure 3 shows the dose response of sprout for-
mation to purified recombinant Ang1*. Significant stimu-
lation was seen at a concentration of 220 ng/ml
(equivalent to 1.7 nM with Ang1 as a dimer). It is not clear
why previous assays in vitro (such as tube-formation assays
[5,6]) have failed to reveal any biological activity. Differ-
ences in the cells, cell confluency (which affects receptor
expression), assay conditions and/or extracellular matrix
are of considerable importance in these in vitro assays and
may determine the particular response. Apart from those
differences, there is a principle difference between
sprouting/invasion assays that require active migration
and possibly proliferation, and tube-formation assays that
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Figure 1
Assay for sprout formation in vitro. ACE cells
on MC beads in three-dimensional fibrin gels
incubated with control (a,b) or Ang1-
containing (c,d) samples. (a,c) Phase-contrast
photomicrographs; (b,d) nuclear staining with
Hoechst 33324 showing the number of
endothelial cells that make up individual
sprouts in (c). The assay for angiogenesis in
vitro was carried out as described by Nehls
and Drenckhahn [8] with slight modifications.
Briefly, ACE cells were grown to confluence
on MC beads (Sigma) and placed in a
2.5 mg/ml fibrinogen gel (Sigma) containing
Ang1, VEGF or controls, and 200 U/ml
Trasylol (Bayer). Clotting was started by the
addition of 2.5 U/ml thrombin (Sigma). Fibrin
gels were incubated in DMEM containing the
appropriate concentration of factors, 0.1%
calf serum and 200 U/ml Trasylol. After two
days, gels were fixed with 4%
paraformaldehyde, and the number of capillary
sprouts with length exceeding the diameter of
the MC bead (150 µm) was determined for
every 50 MC beads counted. The scale bar
represents 150 µm.
Figure 2
Sprout formation assays were performed using media conditioned by
control or Ang1-producing cell lines. In each case, the number of
capillary sprouts per 50 MC beads was counted. As described in the
legend to Figure 1, only those capillary sprouts with length exceeding
the diameter of the MC bead were counted. Values are mean ± s.e.m.
(n = 6). 
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Figure 3
Dose-response of sprout formation in purified Ang1* or VEGF. Values
are mean ± s.e.m. (n = 6). Significance was determined by the Student
t test. Recombinant Tie2–IgG fusion protein (20 µg/ml) was used to
inhibit Ang1* activity. Irrelevant IgG fusion proteins did not inhibit
sprout formation in response to Ang1 (data not shown).
0
5
10
15
20
25
30
0 20 74 220 670 2000 670
+ Tie2
1 10
N
um
be
r o
f c
ap
ill
ar
y 
sp
ro
ut
s 
pe
r 5
0 
M
C
 b
ea
ds
Ang1* concentration
(ng/ml)
p 
=
 0
.0
43
8
p  
=
 0
.0
00
2
VEGF  
concentration
(ng/ml)Current Biology
just require a reorganization of cells. Ang1 and Ang1*
have repeatedly failed to show activity in tube-formation
assays. Of course, we cannot exclude the possibility that
some variation of the assay or some factor combination
would reveal some activity.
VEGF also induced sprout formation (Figure 3) that was
not inhibited by Tie2–IgG (data not shown). When tested
at suboptimal doses, VEGF (1 ng/ml) and Ang1
(220 ng/ml) acted synergistically to induce sprout forma-
tion (Figure 4). Unlike VEGF, Ang1 possesses only very
weak mitogenic activity for endothelial cells (Figure 5).
This suggests that the combined activity of these factors
may induce synergistic signaling events in endothelial
cells, leading to the formation of new capillaries by sprout-
ing from pre-existing vessels. 
Signal transduction pathways that are involved in the
sprouting of capillaries have not yet been identified.
Filopodia formation triggered by small GTPases of the
cdc42 family, migration and localized proteolytic activity
provided by the plasmin or metalloprotease systems all
seem to participate in this complex process. It will be
important to determine the contribution of the VEGF and
angiopoietin receptor systems in the regulation of these
activities. In any case, the specific early embryonic lethali-
ties in mice deficient for the Ang1 ligand and the Tie2
receptor have demonstrated the essential role of this
ligand–receptor pair in sprouting angiogenesis (although
less dramatic in the case of Ang1 than Tie2) and remodel-
ing of pre-existing vascular plexus [4,5]. In addition, peri-
cyte and smooth muscle cell recruitment has been
proposed to be regulated by this ligand–receptor system
[3,10]. Whether the remodeling and/or recruitment
processes involve similar or different activities as the
sprouting process, or require the action of additional
ligands such as Ang2 or receptors such as Tie1, remains to
be determined. Our results show that Ang1 is a potent
inducer of sprouting angiogenesis. Inhibition of this activ-
ity may have implications for the therapeutic intervention
of pathological angiogenesis, such as in solid tumors.
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Figure 4
Synergistic effect of Ang1 and VEGF. The combined stimulation using
the suboptimal doses (see Figure 3) of VEGF (1 ng/ml) and Ang1*
(220 ng/ml) results in a larger increase in the number of sprouts than
expected for a purely additive action. Values are mean ± s.e.m. (n = 6);
significance was determined by the Student t test.
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Figure 5
Ang1 is only a weak mitogen for endothelial cells. Third-passage
human umbilical vein endothelial cells (5000 per well) were seeded
into a 48-well plate (Nunc). The next day, medium containing 5% FCS
and the indicated amounts of Ang1* and VEGF were added, and the
cells were incubated for 3 days. Cells were counted using a Casy cell
counter (Schärfe System). Ang1* induced a 30% increase in cell
number, which was inhibited by Tie2–IgG (20 µg/ml), whereas VEGF
induced a more than twofold increase.
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